The protein moiety of the Brucella Omp19 lipoprotein, co-administered as oral adjuvant, induces a Th1 immune response

ANDRÉS E. IBAÑEZ; LORENA M. CORIA; KARINA A. PASQUEVICH; PAULA BARRIONUEVO; MARIA VICTORIA DELPINO; GUILLERMO H. GIAMBARTOLOMEI; JULIANA CASSATARO

Buenos Aires

Congreso; First French-Argentine Inmunology Congress; 2010

Previous results demonstrate that the protein moiety of the Brucella Omp19 lipoprotein (U-Omp19) administered by the oral route has self-adjuvant properties. These prompt us to study its mucosal adjuvant capacity using as a model antigen ovalbumin (OVA). For this purpose mice were immunized orally with OVA, U-Omp19+OVA, or choleric toxin (CT)+OVA. By flow cytometry we determined that the percentage of CD4+ and CD8+ T cells expressing a4b7 integrin increased in those mesenteric lymph nodes from U-Omp19+OVA (CD4+ a4b7+: 7,7%; CD8+ a4b7+:12,16%) and CT+OVA (7,15%; 16,46%) in comparison with OVA (0,74%; 1,64%) immunized mice. We also observed a significant delayed type hypersensitivity (DTH) response to OVA injection in U-Omp19+OVA (d=0,11mm, P